There was weak evidence for an association of genetically proxied ACE inhibition with lower risk of stroke (OR 0.94, 95% CI 0.88 to 1.01; P = 0.06) and coronary artery disease (OR 0.95, 95% CI 0.89 to 1.02; P = 0.16). This evidence concerns the gene ACE and coronary artery disorder.